Johnson & Johnson

Receive alerts
Market Cap:
$344.68 billion
52 weeks high
52 weeks low

Viewing results 1-25 of 68


Could psychedelic medicine be the new cannabis?

Much like cannabis, psychedelic compounds have often been maligned by mainstream society for their connection with recreational drug use....

2 weeks, 3 days ago

CB2 Insights names former Johnson & Johnson executive to its board of directors

Peter Cummins worked for more than two decades at Johnson & Johnson in a variety of executive roles...

2 weeks, 6 days ago

Buds & Duds: Cannabis stocks in the green; CB2 Insights gets boost from former Johnson & Johnson executive

Also on the move were Cannvas MedTech, Harvest Health & Recreation, Canopy Growth and Choom...

2 weeks, 6 days ago

Seelos Therapeutics has catalysts for its ketamine depression drug, multiple shots on goal with a strong pipeline

The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue...

on 25/4/19

Seelos Therapeutics’ blockbuster ketamine drug could be the next wonder antidepressant

The New York-based clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating strong revenue...

on 17/4/19
Retail & consumer

Could psychedelic medicine be the new cannabis?

Recent developments have indicated that new treatments derived from these mind-altering substances are garnering new attention from the investment community...

on 29/3/19

Coverage of Geron kicks off at BTIG with a Buy rating

BTIG analyst Thomas Shrader suggests the stock has been 'left for dead' unfairly...

on 14/2/19

ROBO Global says 3D printing poised for a high-growth, ‘profitable future’

A senior research analyst at Robo Global writes that with major industries investing heavily in 3D printing, the sector is a ‘key area of focus’ for investors in the robotics, automation and artificial intelligence space...

on 5/2/19

MeiraGTx surges on collaboration with J&J unit on retinal diseases

The arrangement calls for cooperation in clinical development and preclinical programs...

on 1/2/19

Admedus appoints new chief medical officer to focus on growth opportunities

Dr Kiran Bhirangi has a deep knowledge of international regulatory and reimbursement environments, having worked across device development, launch and evaluation. ...

on 4/12/18
Industry & services

ShareRoot granted ASX trading halt pending capital raising announcement

The halt will remain until Friday, November 16, or when an announcement is released to the market....

on 14/11/18

ShareRoot increases the Social Science takings amid MediaConsent interest

The consumer data security provider is aiming to grow revenue and reduce spending in the coming year....

on 12/11/18

Johnson & Johnson third-quarter results beat estimates; raises guidance for 2018

Company's sterling performance relied on its pharmaceutical, consumer and medical device businesses...

on 17/10/18

Johnson & Johnson ordered to pay US$4.7bn in damages to women in talc cancer case

The women alleged J&J knew its talc contained asbestos since the 1970s and covered up the evidence...

on 13/7/18
Retail & consumer

J&J hit with US$21.7mln verdict in second talcum powder-cancer trial

The New Jersey-based health care giant lost a second trial linking baby powder use to deadly asbestos cancer...

on 25/5/18

Pharma sales turbocharge Johnson & Johnson’s first-quarter earnings beat

Results exceeded Wall Street expectations for earnings and revenue...

on 17/4/18

Johnson & Johnson, Imerys may face more suits related to baby powder, Reuters Says

Two companies were ordered to pay a total of US117mln...

on 16/4/18

Johnson & Johnson, Imerys ordered to pay additional US$80mln in punitive damages in talc-cancer case

A New Jersey state court jury awarded the damages today, the report says...

on 12/4/18

Johnson & Johnson, Imerys ordered by court to pay at least US$37mln in asbestos suit

Investment banker claimed asbestos in talc product caused cancer...

on 7/4/18

Johnson & Johnson receives US$2.1bn offer for LifeScan Inc. from Platinum Equity

LifeScan makes blood glucose monitoring products for people with diabetes...

on 17/3/18

New tax law drags Johnson & Johnson’s fourth quarter into red territory but sales up

The new tax law saw the company make a provisional tax charge of US$13.27bn...

on 24/1/18

Johnson & Johnson, Chesapeake Energy, Verizon Communications and more - PRE-MARKET

Wall Street shares are seen starting mixed - what else is happening in pre-market deals?...

on 24/1/18

Abbott Laboratories, Apple Inc, Lennar and Wynn Resorts Ltd - PRE-MARKET

Proactive takes a look at pre-market trade in New York, and picks out some highlights ...

on 3/1/18